HNN3.0
Register
Register
Register

Project cooperationUpdated on 8 January 2026

Modified Vaccinia Ankara (MVA) platform for strong T-cell immune responses

Head of Technology Development at ReiThera srl

Rome, Italy

About

ReiThera offers its consolidated Modified Vaccinia Ankara (MVA) platform as an R&D- and GMP-ready viral vector technology supporting the development of vaccines and cancer immunotherapies requiring strong T-cell–mediated immune responses.

MVA is a highly attenuated poxvirus vector with an established clinical safety profile and a strong capacity to induce cellular immunity. Its biological features make it suitable for both infectious disease prevention and oncology applications, including therapeutic cancer vaccines and immune-modulating strategies where robust T-cell activation is critical.

ReiThera’s expertise spans the full development continuum, from recombinant MVA vector design to scalable manufacturing process development and GMP production. This enables efficient translation of MVA-based candidates from preclinical research into clinical supply, supporting programs with clear translational and regulatory objectives.

As an SME technology and manufacturing partner, ReiThera can contribute to collaborative projects through:

  • Design and engineering of recombinant MVA vectors

  • Scalable and GMP-compatible manufacturing process development and optimization

  • Definition of analytical methods and quality control strategies

  • Translational support for vaccine and oncology clinical programs

This offering is relevant for Horizon Europe projects addressing public health preparedness, vaccine innovation, and unmet needs in oncology, where platforms capable of inducing strong cellular immune responses and supporting clinical translation are required.

ReiThera aims to participate in collaborative consortia by providing its MVA platform and industrial know-how, without acting as project coordinator.

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential

Organisation

ReiThera srl

Company (SME)

Rome, Italy

Similar opportunities

  • Project cooperation

    Adenoviral vaccine platform

    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential

    Angelo Raggioli

    Head of Technology Development at ReiThera srl

    Rome, Italy

  • Project cooperation

    process development & GMP manufacturing of viral vectors

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)

    Stefania Capone

    Grant Projects Director at ReiThera srl

    Rome, Italy

  • Project cooperation

    Transfection-free AAV production

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)

    Angelo Raggioli

    Head of Technology Development at ReiThera srl

    Rome, Italy